SCHEMBL30507101

SCHEMBL30507101

O=C1Nc2ccc(Cl)cc2C12CCN(CCOc1ccc(S(=O)(=O)C3CC(O)C3)cc1)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.42
HTR7 P34969 7/20 0.42
HTR2A P28223 5/20 0.42
HTR6 P50406 5/20 0.42
IP6K1 Q92551 5/20 0.41
HRH3 Q9Y5N1 3/20 0.39
FLT3 P36888 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
LRRK2 Q5S007 1/20 0.39
KCNA5 P22460 1/20 0.39
IP6K3 Q96PC2 1/20 0.38
IP6K2 Q9UHH9 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25319509 1.00 HTR1A (0.42) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL25319636 1.00 HTR1A (0.42) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL30506829 1.00 HTR1A (0.42) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL25315441 1.00 HTR1A (0.42) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL30506972 1.00 HTR1A (0.42) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL25314767 0.91 HTR1A (0.46) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL30507163 0.91 HTR1A (0.46) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL30506835 0.85 HTR1A (0.44) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL25315499 0.85 HTR1A (0.44) HTR1AHTR7HTR2AHTR6IP6K1
SCHEMBL25318732 0.83 IP6K1 (0.43) HTR1AHTR7HTR2AHTR6IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 EP disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed